Dance Biopharm Holdings, Inc.

Transforming the Treatment of Chronic Diseases with Inhaled Biologics

Developing soft mist inhaled biologics to address important unmet patient and clinical needs, starting with Diabetes. Check out our device in the video below!

View Video
Dance Biopharm Inhaler

About Dance Biopharm

Dance Biopharm is a private company focused on developing novel inhaled formulations of biologics to treat severe and chronic diseases. The company’s novel inhalation delivery technology platform may be utilized with liquid formulations of biologics with the goal of providing effective and convenient treatment options to patients along with wireless connectivity to improve disease management. Dance, headquartered in Durham, NC, was founded by John Patton, Ph.D., who has over 25 years of experience developing numerous inhaled therapies.

Introducing Dance 501

Dance-501 is an investigational drug-device combination under development for treatment of diabetes with the intent to eliminate the need for injections for mealtime insulin. Dance-501 includes a liquid formulation of natural human insulin and a small silent handheld electronic aerosol device, intended to deliver the patient’s individualized dose of insulin in 1-3 breaths at mealtime. Dance-501 technology allows for efficient insulin delivery and the potential to make inhaled insulin easy and economical.

View Pipeline

Press Releases

Dance Biopharm Presents Encouraging Data from Phase 2 Clinical Trial of Dance 501 Inhaled Insulin Therapy at American Diabetes Association Meeting

- Faster onset of action shown for Dance 501 compared to subcutaneous injection of insulin lispro – - No changes in lung function and no cough observed in patients

More News